Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.52 |
| ▸ | MPO | P05164 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | DPYD | Q12882 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20515400 | 1.00 | DHFR (0.52) | DHFRMPONR4A2MEN1KMT2A | |
| SCHEMBL19380925 | 0.87 | DHFR (0.48) | DHFRMPOMEN1KMT2AMAPK1 | |
| SCHEMBL18618863 | 0.86 | DHFR (0.53) | DHFRMPOMEN1KMT2AMAPK1 | |
| SCHEMBL20672109 | 0.86 | MAPT (0.44) | MPOMEN1KMT2AMAPK1HTT | |
| SCHEMBL20515396 | 0.84 | MPO (0.47) | DHFRMPOMEN1KMT2AMAPK1 | |
| SCHEMBL18618821 | 0.84 | MPO (0.47) | DHFRMPOMEN1KMT2AMAPK1 | |
| SCHEMBL17596066 | 0.81 | MPO (0.46) | DHFRMPOMEN1KMT2AMAPK1 | |
| SCHEMBL17596065 | 0.81 | MPO (0.46) | DHFRMPOMEN1KMT2AMAPK1 | |
| SCHEMBL18586036 | 0.81 | MAPT (0.45) | DHFRMPONR4A2KMT2A | |
| SCHEMBL18586035 | 0.81 | MAPT (0.45) | DHFRMPONR4A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180282320-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2018-10-04 | — | — | US | disclosed |
| WO-2017040451-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282320-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | DHFR 1044/4885MPO 2/4885NR4A2 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.